Status:
WITHDRAWN
A Long Term Safety Study of Apricitabine in HIV-infected Patients
Lead Sponsor:
Avexa
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX...
Detailed Description
The clinical study AVX-301 studies the efficacy and safety of 800mg and 1200mg BID ATC in combination with an optimized background in patients who are HIV-1 infected and have failed treatment with emt...
Eligibility Criteria
Inclusion
- Patients who complete studies AVX-301 or AVX-302 or :Patients who meet the criteria for virologic failure/lack of response in study AVX-301 or AVX-302
- 18 years of age, or older
- Male, or non-pregnant, non-breastfeeding female patients, who agree to comply with the applicable contraceptive requirements of the protocol.
Exclusion
- Prior withdrawal from AVX-301 or AVX-302
- Current acute or chronic hepatitis B virus infection
- Current treatment for hepatitis C virus infection
- Renal Function not adequate
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00686270
Start Date
May 1 2008
End Date
May 1 2012
Last Update
June 23 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.